GENinCode PLC - Oxford-based biotechnology company focused on risk assessment and prediction of cardiovascular diseases - Files pre-submission for Cardio inCode-Score with the US Food & Drug Administration. Cardio inCode-Score is an in-vitro diagnostic test which assesses an individual's combined genetic and clinical risk to predict and prevent cardiovascular disease. The pre-submission marks the commencement of the regulatory pathway for US market approval, which GENinCode adds is anticipated later this year.
Current stock price: 32.60 pence, up 1.9% in London
12-month change: down 23% since July
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Genincode (GENI)